dc.contributor.author |
Chisholm, D. |
en_US |
dc.contributor.author |
Gureje, O. |
en_US |
dc.contributor.author |
Saldivia, S. |
en_US |
dc.contributor.author |
Villalon Calderon, M. |
en_US |
dc.contributor.author |
Wickremasinghe, R. |
en_US |
dc.contributor.author |
Mendis, N. |
en_US |
dc.contributor.author |
Ayuso-Mateos, J. L. |
en_US |
dc.contributor.author |
Saxena, S. |
en_US |
dc.date.accessioned |
2014-10-29T09:26:48Z |
|
dc.date.available |
2014-10-29T09:26:48Z |
|
dc.date.issued |
2008 |
en_US |
dc.identifier.citation |
Bulletin of the World Health Organization. 2008; 86(7): pp.542-51 |
en_US |
dc.identifier.issn |
0042-9686 (Print) |
en_US |
dc.identifier.issn |
1564-0604 (Electronic) |
en_US |
dc.identifier.uri |
http://repository.kln.ac.lk/handle/123456789/1839 |
|
dc.description |
Indexed in MEDLINE |
|
dc.description.abstract |
OBJECTIVE: Schizophrenia is a highly disabling disease and is costly to treat. We set out to establish what are the most cost-effective interventions applicable to developing regions and countries. METHODS: Analysis was undertaken at the level of three WHO subregions spanning the Americas, Africa and South-East Asia, and subsequently in three member states (Chile, Nigeria and Sri Lanka). A state transition model was used to estimate the population-level health impact of older and newer antipsychotic drugs, alone or in combination with psychosocial intervention. Total population-level costs (in international dollars or local currencies) and effectiveness (measured in disability-adjusted life years averted) were combined to form cost-effectiveness ratios. FINDINGS: The most cost-effective interventions were those using older antipsychotic drugs combined with psychosocial treatment, delivered via a community-based service model (I$ 2350-7158 per disability-adjusted life year averted across the three subregions, I$ 1670-3400 following country-level contextualisation within each of these subregions). The relative cost-effectiveness of interventions making use of newer, "atypical" antipsychotic drugs is estimated to be much less favourable. CONCLUSION: By moving to a community-based service model and selecting efficient treatment options, the cost of substantially increasingtreatment coverage is not high (less than I$ 1 investment per capita). Taken together with other priority-setting criteria such as disease severity, vulnerability and human rights protection, this study suggests that a great deal more could be done for persons and families living under the spectre of this disorder |
|
dc.publisher |
World Health Organization |
en_US |
dc.title |
Schizophrenia treatment in the developing world: an interregional and multinational cost-effectiveness analysis |
en_US |
dc.type |
Article |
en_US |
dc.identifier.department |
Public Health |
en_US |
dc.creator.corporateauthor |
World Health Organization |
en_US |